DUONEB
Combination product
Pronunciation: al-BYOO-ter-ol and ip-ra-TROE-pee-um (DOO-oe-neb)
Combination of Albuterol and Ipratropium.
Each component keeps its own pharmacology page; the combination itself adds no new mechanism.
Components (2)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Bronchospasm associated with COPD (requiring >1 bronchodilator) | Adults | One 3 mL vial QID via nebulizer | Up to 2 additional 3 mL doses/day if needed |
Renal Undefined
Hepatic Undefined
Instructions
- Administer via jet nebulizer with mouthpiece or face mask
Available strengths
- sol 0.083/0.017 %
- spray 100/20 mcg/inh
Contraindications
- Hypersensitivity to atropine and its derivatives
Cautions
- Paradoxical bronchospasm
- Cardiovascular effects
- Narrow-angle glaucoma / acute eye pain
- Urinary retention
- Hypersensitivity reactions
Adverse reactions
- Chest pain
- Lung disease/COPD exacerbation, pharyngitis, bronchitis
- Dyspepsia, nausea, diarrhea
- Leg cramps
- Constipation, voice alteration
Pregnancy Albuterol Pregnancy Category C (teratogenic in animals); ipratropium Category B.
Lactation Undefined
Cost
DUONEB
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.083/0.017 % | sol | per unit | not offered |
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. DUONEB is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Part D rank #225.